Understanding the Side Effects of Ozempic and Wegovy

Last reviewed: July 6, 2026

Last updated: July 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists have transformed weight management for millions, with clinical trials showing average weight loss of 15–22% over 68 weeks. However, like all medications, these compounds carry side effects that range from mild gastrointestinal symptoms to serious but rare complications. Understanding what to expect helps patients make informed decisions and work with their provider to maximize benefit while minimizing discomfort.

Common GLP-1 Side Effects and How They Develop

The most frequently reported side effects of semaglutide and tirzepatide are gastrointestinal in nature. Nausea, vomiting, diarrhea, and constipation occur because GLP-1 slows stomach emptying and increases feelings of fullness—the same mechanisms that drive weight loss. In clinical trials, roughly 25–40% of patients experience nausea during the first weeks, though severity typically decreases as the body adapts. Starting at low doses and titrating gradually helps the digestive system adjust without forcing discontinuation.

Appetite suppression is not technically a side effect but the intended pharmacological action. Patients report reduced interest in food, smaller portion sizes, and diminished cravings for high-calorie items. This can occasionally lead to unintentional undereating or nutrient gaps if protein and micronutrient intake is not prioritized. A registered dietitian can help ensure adequate nutrition during treatment, especially during the adjustment phase.

Serious but Rare GLP-1 Safety Concerns

Thyroid C-cell tumors were observed in animal studies at very high doses, leading to black-box warnings on semaglutide and tirzepatide. However, no human cases have been documented in clinical trials or post-market surveillance spanning millions of patients. Current guidelines recommend avoiding these medications in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Anyone with thyroid concerns should disclose them during the PlexusDx intake process.

Pancreatitis, retinal complications, and gallbladder disease have been reported rarely in post-market data. Patients should seek immediate care if they experience severe abdominal pain, sudden vision changes, or persistent right upper quadrant discomfort. PlexusDx compounded semaglutide and tirzepatide carry the same safety profile as brand-name versions because the active pharmaceutical ingredients are identical; they come from licensed 503A compounding pharmacies that follow FDA standards.

Managing Side Effects with Gradual Dose Escalation

PlexusDx follows a conservative titration protocol to minimize tolerability issues. Starting doses are lower than many telehealth competitors, allowing the body to acclimate before increases. Your dose may need to go up—your price won't. This flat-rate pricing model ($149–$189 per month for semaglutide injection, depending on commitment tier) removes financial barriers to finding your optimal therapeutic window without overpaying for higher doses.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Choosing the Right Formulation to Reduce Side Effects

PlexusDx offers multiple delivery options: compounded semaglutide injection, oral semaglutide, compounded tirzepatide injection, and oral tirzepatide. Injectable formulations typically produce stronger and faster effects, which some patients experience as more pronounced side effects during the first 1–2 weeks. Oral formulations deliver slower absorption and may suit patients seeking a gentler start, though efficacy data favors injections. The Microdose GLP-1 Protocol ($129/mo flat) combines ultra-low-dose semaglutide with behavioral coaching for patients prioritizing tolerability over rapid weight loss.

For patients who experience significant nausea or gastrointestinal upset on single-agent therapy, the GLP-Squared Injection ($289/mo) combines semaglutide and tirzepatide at complementary doses. This dual-compound approach leverages different receptor affinities to distribute metabolic load across pathways, potentially reducing peak side-effect intensity while sustaining weight-loss efficacy. HSA/FSA eligibility applies to all formulations, and no insurance is required—PlexusDx serves all 50 states.

When to Contact Your Provider About Side Effects

Mild nausea, occasional loose stools, and fatigue during week 1–3 are expected and usually resolve within days to weeks. However, persistent vomiting that prevents oral intake, severe abdominal pain, dizziness, or chest discomfort warrant immediate medical evaluation. PlexusDx patients have 24/7 access to their care team and can report adverse events for real-time clinical guidance. Do not stop your medication abruptly without provider approval, as sudden discontinuation can lead to blood sugar fluctuations and rapid weight regain.

Long-term side effects are rare and most patients tolerate semaglutide and tirzepatide well beyond the adjustment phase. Staying hydrated, eating protein-rich foods even when appetite is suppressed, and maintaining moderate physical activity all support tolerability. Annual follow-ups via telehealth allow your PlexusDx provider to assess side-effect burden, adjust dosing, and order periodic labs to ensure metabolic safety.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Will nausea from semaglutide or tirzepatide go away?

Yes, in most patients. Nausea peaks during the first 1–3 weeks and typically resolves as your body adapts. PlexusDx's gradual titration protocol and starting prices ($189/mo for semaglutide injection) help minimize early nausea by allowing slower dose escalation. If nausea persists, your provider can adjust your dose, switch formulations, or explore the Microdose Protocol.

Can I take anti-nausea medication while on GLP-1 therapy?

Yes. Over-the-counter remedies like ginger, peppermint, or antihistamines can be safe adjuncts during adjustment. Prescription anti-nausea drugs (ondansetron, metoclopramide) should be discussed with your PlexusDx provider, as metoclopramide may interfere with GLP-1 effects by speeding stomach emptying. Your care team will help you find the right combination.

How much does PlexusDx compounded semaglutide cost compared to Ozempic or Wegovy?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) with no insurance required, no membership fee, and HSA/FSA eligibility. Brand-name Ozempic and Wegovy typically cost $900–$1,300/mo after insurance or cash pay. Your dose may need to go up—your price won't, ensuring affordability across all dose tiers.

Are there serious side effects I should watch for?

Serious side effects are rare but include acute pancreatitis (severe abdominal pain), vision changes, and gallbladder disease. Thyroid concerns apply mainly to those with medullary thyroid carcinoma history. Seek immediate care for chest pain, severe vomiting, or signs of dehydration. PlexusDx screens all patients during intake and monitors for safety throughout treatment.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. The test ($298) analyzes GIPR and FTO, and MC4R variants across 14 pathways to identify genetic predispositions to nausea, appetite suppression intensity, and metabolic response. This data guides dose adjustments and formulation selection, helping PlexusDx personalize your treatment to reduce side-effect burden while maximizing weight-loss results.

Related Reading

• Ozempic Side Effects
• Wegovy Side Effects
• Wegovy Vs Ozempic 2
• Ozempic Vs Wegovy 2

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.